RxDoctor Payments Data

Cynthia Allen

Family · Osgood, INNPI 1336379353

Payments from drug & device makers

$603in general payments, 2019–2025

Across 14 payments — averaging $43.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Curonix LLC$420
  • Novo Nordisk$61
  • Exact Sciences$26
  • Pfizer$24
  • Medtronic$20
  • Novartis$14
  • plus $37 from 3 others

What the payments were for

  • Travel & lodging$42070%
  • Food & beverage$18230%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Curonix LLC2$420
Novo Nordisk4$61
Exact Sciences1$26
Pfizer2$24
Medtronic1$20
Novartis1$14
Amgen1$14
GSK1$12
Alkermes, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$603 in reported general payments places this provider in the 55th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$16,332
Medicare patients
75
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$84,499
MounjaroTirzepatide34$41,010
RybelsusSemaglutide23$39,202
JardianceEmpagliflozin32$28,621
EliquisApixaban26$23,833
TrulicityDulaglutide16$15,114
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,917
Arnuity ElliptaFluticasone Furoate12$2,458
Advair DiskusFluticasone Propion/Salmeterol12$2,365
Duloxetine Hcl49$1,863
Atorvastatin Calcium280$1,705
Albuterol Sulfate HfaAlbuterol Sulfate50$1,532
Omeprazole155$1,517
Levothyroxine Sodium175$1,351
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$61$123,70174 claims
PfizerEliquis$24$23,83326 claims
GSKArnuity Ellipta$12$2,45812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,392 family providers in Indiana.

Other family in Osgood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →